Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 118
Filter
1.
Rev Esp Quimioter ; 36 Suppl 1: 15-17, 2023 Nov.
Article in English | MEDLINE | ID: mdl-37997864

ABSTRACT

Despite the fact that COVID is today not a life-threat for the general population, recipients of solid organ transplantation should be viewed as a high risk group for severe COVID. Repetitive doses of SARS-CoV-2 vaccine still fail to protect SOT recipients from infection, disease or even death caused by COVID. A more frequent need for medical care may initially place these patients at greater chances of SARS-CoV-2 infection. Immunosuppression after engrafting and underlying medical conditions that led to the practice of SOT contribute to more risk of severe infection. Immunosuppression also blunts the intensity of humoral and cellular responses after vaccination, even when several booster doses have been administered. Still, vaccination is the best strategy to prevent a fatal outcome in case of SARS-CoV-2 infection, with a particular reduction in mortality. SOT recipients should be considered a high-risk population that need yearly SARS-CoV-2 vaccination.


Subject(s)
COVID-19 , Organ Transplantation , Humans , COVID-19 Vaccines , SARS-CoV-2 , Transplant Recipients , Organ Transplantation/adverse effects
2.
Rev Esp Quimioter ; 35 Suppl 3: 2-5, 2022 Oct.
Article in English | MEDLINE | ID: mdl-36285848

ABSTRACT

SARS-CoV-2 infection now seems to have entered the announced endemic phase. The population's immunity is increasingly more robust, thanks to successive vaccination and booster campaigns, and the almost inevitable exposure and re-exposure to the virus itself, which has truly served as a natural immunizing mechanism. On the other hand, the genetic drift of the virus is leading it to become another catarrhal agent, as are the other endemic human coronaviruses. However, it should not be lost sight of that there are still segments of the population with susceptibility to severe COVID, who will be candidates to continue receiving vaccine boosters or antiviral drugs in the initial stages of infection.


Subject(s)
COVID-19 , Humans , SARS-CoV-2 , COVID-19 Vaccines , Antiviral Agents/therapeutic use , Vaccination
3.
Rev Esp Quimioter ; 34 Suppl 1: 46-48, 2021 Sep.
Article in English | MEDLINE | ID: mdl-34598426

ABSTRACT

Detection of SARS-CoV-2 proteins is commercially available in the form of lateral-flow rapid antigen test for the point-of-care diagnosis of COVID-19. This platform has been validated for symptomatic and asymptomatic individuals, for diagnosis or screening, and as part of single or sequential diagnostic strategies. Although in general less sensitive than amplification techniques, antigen tests may be particularly valid during the first days of symptoms and to detect individuals with greater viral load, thereby with enhanced chances of viral transmission. The simplicity of antigen tests make them very suitable to discard infection in settings with low pretest probability, and to detect infection in case of higher chances of having COVID-19.


Subject(s)
COVID-19 , COVID-19 Nucleic Acid Testing , Humans , Mass Screening , SARS-CoV-2 , Sensitivity and Specificity
4.
Rev Esp Quimioter ; 34 Suppl 1: 76-80, 2021 Sep.
Article in English | MEDLINE | ID: mdl-34598434

ABSTRACT

After more than a year of pandemic, the international medical community has changed the perception of fear to one of respect for SARS-COV-2. This has been the consequence of the integral study of all the dimensions of the disease, from viral recombinant capacity to transmissibility, diagnosis, care and prevention. This document summarizes the main strategic lines of study and approach to the pandemic in Madrid.


Subject(s)
COVID-19 , Pandemics , Humans , Pandemics/prevention & control , SARS-CoV-2
5.
Rev Esp Quimioter ; 34(4): 280-288, 2021 08.
Article in English | MEDLINE | ID: mdl-33752321

ABSTRACT

We describe the most widely used temporary hospital in Europe during the first pandemic wave, its structure, function, and achievements. Other models of care developed during the pandemic around the world were reviewed including their capacity, total bed/ICU bed ratio and time of use. We particularly analyzed the common and differential characteristics of this type of facilities. IFEMA Exhibition Center was transformed into a temporary 1,300-bed hospital, which was in continuous operation for 42 days. A total of 3,817 people were treated, generally patients with mild to moderate COVID-19, 91% of whom had pneumonia. The average length of stay was 5 to 36 days. The most frequent comorbidities were hypertension (16.5%), diabetes mellitus (9.1%), COPD (6%), asthma (4.6%), obesity (2.9%) and dementia (1.6%). A total of 113 patients (3%) were transferred to another centers for aggravation, 19 (0.5%) were admitted to ICU and 16 patients (0.4%) died. An element of great help to reducing the overload of care in large hospitals during peaks of health emergencies could be these flexible structures capable of absorbing the excess of patients. These must be safe, breaking domestic transmission and guarantee social and emotional needs of patients. The success of these structures depends on delimitation in admission criteria taking into account the proportion of patients who may require, during admission, assistance in the critical care area.


Subject(s)
COVID-19 , Hospital Administration , Hospitals/statistics & numerical data , Pandemics , Critical Care , Europe , Humans , Intensive Care Units
6.
Rev Esp Quimioter ; 33(6): 466-484, 2020 Dec.
Article in English | MEDLINE | ID: mdl-33070578

ABSTRACT

The high transmissibility of SARS-CoV-2 before and shortly after the onset of symptoms suggests that only diagnosing and isolating symptomatic patients may not be sufficient to interrupt the spread of infection; therefore, public health measures such as personal distancing are also necessary. Additionally, it will be important to detect the newly infected individuals who remain asymptomatic, which may account for 50% or more of the cases. Molecular techniques are the "gold standard" for the diagnosis of SARS-CoV-2 infection. However, the massive use of these techniques has generated some problems. On the one hand, the scarcity of resources (analyzers, fungibles and reagents), and on the other the delay in the notification of results. These two facts translate into a lag in the application of isolation measures among cases and contacts, which favors the spread of the infection. Antigen detection tests are also direct diagnostic methods, with the advantage of obtaining the result in a few minutes and at the very "pointof-care". Furthermore, the simplicity and low cost of these tests allow them to be repeated on successive days in certain clinical settings. The sensitivity of antigen tests is generally lower than that of nucleic acid tests, although their specificity is comparable. Antigenic tests have been shown to be more valid in the days around the onset of symptoms, when the viral load in the nasopharynx is higher. Having a rapid and real-time viral detection assay such as the antigen test has been shown to be more useful to control the spread of the infection than more sensitive tests, but with greater cost and response time, such as in case of molecular tests. The main health institutions such as the WHO, the CDC and the Ministry of Health of the Government of Spain propose the use of antigenic tests in a wide variety of strategies to respond to the pandemic. This document aims to support physicians involved in the care of patients with suspected SC2 infection, in the context of a growing incidence in Spain since September 2020, which already represents the second pandemic wave of COVID-19.


Subject(s)
Antigens, Viral/blood , COVID-19 Serological Testing/methods , COVID-19/diagnosis , Consensus , Pandemics , SARS-CoV-2/immunology , Acute Disease , Adolescent , Adult , Age Distribution , Aged , Aged, 80 and over , Algorithms , COVID-19/epidemiology , COVID-19/mortality , COVID-19/transmission , COVID-19 Nucleic Acid Testing/standards , COVID-19 Serological Testing/standards , Child , Child, Preschool , Contact Tracing , Emergencies , Female , Humans , Incidence , Infant , Male , Middle Aged , Nasopharynx/virology , Sensitivity and Specificity , Spain/epidemiology , Specimen Handling/methods , Specimen Handling/standards , Young Adult
7.
Sci Rep ; 9(1): 13974, 2019 09 27.
Article in English | MEDLINE | ID: mdl-31562395

ABSTRACT

Total oil content (OC) is one of the main parameters used to characterize the whole of olives entering a commercial mill, quantified by the total fresh weight of the lot and the oil concentration (%) assessed in a representative sample on olive paste, by means of chemical extraction. Nuclear magnetic resonance (NMR) and NIR spectroscopy are alternative methods even at individual olives. This work evaluates several strategies to calibrate precise NIR models for the estimation of the total OC. To this end, 278 olives were analysed covering whole season variability in terms of olive fresh-weight and the corresponding OC by chemical extraction in 31 batches. The average spectra from hyperspectral NIR images (1003-2208 nm) were computed for each fruit and the actual OC (g) of those olives determined by NMR (0.09 to 1.29 g with a precision of 0.017 g). According to the results, current batch based assessment of the OC (Soxhlet, %) in mills only reproduces 44% of the underlying heterogeneity, despite being the factory standard. The incorporation of individual NIR spectra (278) to the 31 Soxhlet values of the batches allows a 67% explanation of the OC (%) of olives. When estimating OC (g) gathering individual fresh weight and the estimation of oil concentration in olives, a standard error of prediction of 0.061 g is reached (r2 = 0.93), a precision value that approaches the potential limit according to the NMR reference (0.017 g).


Subject(s)
Food Handling/methods , Olea/chemistry , Olive Oil/chemistry , Spectroscopy, Near-Infrared/methods , Calibration
8.
Sci Total Environ ; 688: 632-641, 2019 Oct 20.
Article in English | MEDLINE | ID: mdl-31254829

ABSTRACT

A sub-aerial biofilm (SAB) developed on a granite commonly found in the built cultural heritage of the NW Iberian Peninsula was extracted with 2 different IR irradiations using an Nd:YAG laser at 1064 nm and an Er:YAG laser at 2940 nm. The methodology was based on the application of only one scan in order to evaluate the effect of the laser cleaning operated by applying different consecutive laser scanning and the suitability of these lasers as quick tools. The aim of this comparative study was twofold. The first goal was to find the most satisfactory level of extraction by comparing the results obtained by the different laser sources (IR wavelengths). The other aim was to investigate the by-effects induced by both lasers on each granite-forming mineral. Evaluations were made using stereomicroscopy, Fourier transform infrared spectroscopy, Raman spectroscopy and scanning electron microscopy with energy-dispersive x-ray spectroscopy. The results were interpreted in terms of SAB extraction and damage induced on the granite. The results showed that the Nd:YAG laser achieved the most successful level of cleaning, because it extracted the most SAB, while causing the least amount of damage to the surfaces. Regardless of the fluence applied, the Er:YAG laser did not completely extract the SAB in only one scan; in addition, a more intense melting of biotite grains was found, producing amorphous fusion crusts and losing the distinction of the cleavage planes.


Subject(s)
Biofilms , Infrared Rays , Lasers , Silicon Dioxide
9.
Plant Biol (Stuttg) ; 21(3): 515-522, 2019 May.
Article in English | MEDLINE | ID: mdl-30076674

ABSTRACT

Morphological and functional seed traits have important roles in characterising the species regeneration niche and help to understand the reproductive biology of rare and threatened plants, which can thus support appropriate plant conservation measures. Seed morphometric and dispersal kinetics of the critically endangered Dioscorea strydomiana were measured and compared with those of four other Dioscorea species, and seed germination response under constant temperatures (5-35 °C) was compared with that of the congeneric and widespread D. sylvatica. Seed mass of D. strydomiana (ca. 14 mg) was twice that of D. sylvatica, but similar to or smaller than the other species examined. Seeds of D. strydomiana have the lowest speed of descent and lowest variability in most of the morphological traits considered, suggesting lower phenotypic plasticity but higher variance in the wing-loading value. Seeds of D. strydomiana reached maximum germination at 15 °C (ca. 47%), which decreased slightly to ca. 37% at 25 °C and was completely inhibited at 35 °C. D. sylvatica seeds started to germinate at 10 °C (ca. 3%), reached 75-80% germination at 15-20 °C and maximum (ca. 90%) at 25-30 °C. Base temperatures for germination (Tb ) were 9.3 and 5.7 °C, for D. strydomiana and D. sylvatica, respectively. Due to the higher germination percentages of D. sylvatica, ceiling and optimum temperatures could also be modelled for this species, suggesting higher sensitivity to high temperature for seeds of D. strydomiana. The detected poor seed lot quality of D. strydomiana suggests difficulties in reproduction from seed, highlighting the need for further investigation and conservation actions for this threatened yam species.


Subject(s)
Dioscorea/physiology , Seeds/physiology , Germination/physiology , Plants, Medicinal/physiology , Temperature
10.
Plant Biol (Stuttg) ; 20(3): 602-609, 2018 May.
Article in English | MEDLINE | ID: mdl-29394528

ABSTRACT

Anogeissus leiocarpa (DC.) Guill. & Perr. (Combretaceae) has important economic and cultural value in West Africa as source of wood, dye and medicine. Although this tree is in high demand by local communities, its planting remains limited due to its very low propagation via seed. In this study, X-rays were used to select filled fruits in order to characterise their morphology and seed germination responses to treatment with sulphuric acid and different incubation temperatures. Morphological observations highlighted a straight orthotropous seed structure. The increase in mass detected for both intact and scarified fruits through imbibition tests, as well as morphological observations of fruits soaked in methylene blue solution, confirmed that they are water-permeable, although acid-scarified fruits reached significantly higher mass increment values than intact ones. Acid scarification (10 min soaking in 98% H2 SO4 ) positively affected seed germination rate but not final germination proportions. When intact fruits where incubated at a range of temperatures, no seeds germinated at 10 °C, while maximum seed germination (ca. 80%) was reached at 20 °C. T50 values ranged from a minimum of ca. 12 days at 25 °C to a maximum of ca. 34 days at 15 and 35 °C. A theoretical base temperature for germination (Tb ) of ca. 10 °C and a thermal requirement for 50% germination (S) of ca. 195 °Cd were also identified for intact fruits. The results of this study revealed the seed germination characteristics driven by fruit and seed morphology of this species, which will help in its wider propagation in plantations.


Subject(s)
Combretaceae/physiology , Germination/physiology , Seeds/physiology , Combretaceae/anatomy & histology , Ecology , Fruit/anatomy & histology , Fruit/physiology , Seeds/anatomy & histology , Seeds/metabolism , Temperature , Time Factors , Trees/physiology , Water/metabolism
11.
J Viral Hepat ; 23(1): 47-52, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26390144

ABSTRACT

Patients infected with HIV are at increased risk for cardiovascular disease despite successful antiretroviral therapy. Likewise, chronic hepatitis C virus (HCV) infection is associated with extrahepatic complications, including cardiovascular disease. However the risk of cardiovascular disease has not been formally examined in HIV/HCV-coinfected patients. A retrospective study was carried out to assess the influence of HCV coinfection on the risk of cardiovascular events in a large cohort of HIV-infected patients recruited since year 2004. A composite event of cardiovascular disease was used as an endpoint, including myocardial infarction, angina pectoris, stroke or death due to any of them. A total of 1136 patients (567 HIV-monoinfected, 70 HCV-monoinfected and 499 HIV/HCV-coinfected) were analysed. Mean age was 42.7 years, 79% were males, and 46% were former injection drug users. Over a mean follow-up of 79.4 ± 21 months, 3 patients died due to cardiovascular disease, whereas 29 suffered a first episode of coronary ischaemia or stroke. HIV/HCV-coinfected patients had a greater incidence of cardiovascular disease events and/or death than HIV-monoinfected individuals (4% vs 1.2%, P = 0.004) and HCV-monoinfected persons (4% vs 1.4%, P = 0.5). After adjusting for demographics, virological parameters and classical cardiovascular disease risk factors (smoking, hypertension, diabetes, high LDL cholesterol), both HIV/HCV coinfection (HR 2.91; CI 95%: 1.19-7.12; P = 0.02) and hypertension (HR 3.65; CI 95%: 1.34-9.94; P = 0.01) were independently associated with cardiovascular disease events and/or death in HIV-infected patients. Chronic hepatitis C and hypertension are independently associated with increased cardiovascular disease risk in HIV-infected patients. Therefore, treatment of chronic hepatitis C should be prioritized in HIV/HCV-coinfected patients regardless of any liver fibrosis staging.


Subject(s)
Cardiovascular Diseases/epidemiology , Coinfection/pathology , HIV Infections/pathology , Hepatitis C, Chronic/pathology , Adult , Cardiovascular Diseases/virology , Coinfection/virology , Female , HIV Infections/complications , HIV Infections/virology , HIV-1 , Hepacivirus , Hepatitis C, Chronic/complications , Hepatitis C, Chronic/virology , Humans , Liver Cirrhosis/complications , Male , Retrospective Studies , Risk Factors
12.
Lett Appl Microbiol ; 59(6): 594-603, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25099389

ABSTRACT

UNLABELLED: We propose a model, based on the Gompertz equation, to describe the growth of yeasts colonies on agar medium. This model presents several advantages: (i) one equation describes the colony growth, which previously needed two separate ones (linear increase of radius and of the squared radius); (ii) a similar equation can be applied to total and viable cells, colony area or colony radius, because the number of total cells in mature colonies is proportional to their area; and (iii) its parameters estimate the cell yield, the cell concentration that triggers growth limitation and the effect of this limitation on the specific growth rate. To elaborate the model, area, total and viable cells of 600 colonies of Saccharomyces cerevisiae, Debaryomyces fabryi, Zygosaccharomyces rouxii and Rhodotorula glutinis have been measured. With low inocula, viable cells showed an initial short exponential phase when colonies were not visible. This phase was shortened with higher inocula. In visible or mature colonies, cell growth displayed Gompertz-type kinetics. It was concluded that the cells growth in colonies is similar to liquid cultures only during the first hours, the rest of the time they grow, with near-zero specific growth rates, at least for 3 weeks. SIGNIFICANCE AND IMPACT OF THE STUDY: Mathematical models used to predict microbial growth are based on liquid cultures data. Models describing growth on solid surfaces, highlighting the differences with liquids cultures, are scarce. In this work, we have demonstrated that a single Gompertz equation describes accurately the increase of the yeast colonies, up to the point where they reach their maximum size. The model can be used to quantify the differences in growth kinetics between solid and liquid media. Moreover, as all its parameters have biological meaning, it could be used to build secondary models predicting yeast growth on solid surfaces under several environmental conditions.


Subject(s)
Debaryomyces/growth & development , Models, Biological , Rhodotorula/growth & development , Saccharomyces cerevisiae/growth & development , Zygosaccharomyces/growth & development , Culture Media , Kinetics , Microbial Viability
13.
J Viral Hepat ; 21(7): 475-9, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24750394

ABSTRACT

There is scarce information about the impact of antiviral treatment on subsequent progression of liver fibrosis in HIV-infected patients with chronic hepatitis C who experience different outcomes following peginterferon-ribavirin therapy. We conducted a retrospective study of a cohort of HIV/HCV-coinfected patients with longitudinal assessment of liver fibrosis using elastometry. Patients were split out into four groups according to the prior peginterferon-ribavirin response: sustained virological response (SVR), relapse (R), partial response (PR) and null response (NR). A group of untreated, coinfected patients was taken as control. Significant liver fibrosis progression (sLFP) was defined as a shift from baseline Metavir estimates ≤ F2 to F3-F4, or by >30% increase in liver stiffness in patients with baseline F3-F4. Conversely, significant liver fibrosis regression (sLFR) was defined as a shift from baseline Metavir estimates F3-F4 to ≤ F2, or by >30% reduction in liver stiffness in patients that kept on F3-F4. A total of 498 HIV/HCV-coinfected patients were examined. They were classified as follows: 138 (27.7%) SVR, 40 (8%) R, 61 (12.2%) PR, 71 (14.3%) NR and 188 (37.8%) naive. After a mean follow-up of 53.3 months, sLFP occurred less frequently in patients with SVR (7.2%) compared with R (25%; P = 0.002), PR (23%; P = 0.002), NR (29.6%; P < 0.001) and naïve (19.7%; P = 0.002). Conversely, sLFR was 26.1% in SVR compared with 10% in R (P = 0.03), 14.8% in PR (P = 0.06), 16.9% in NR (P = 0.07) and 10.6% in naïve (P < 0.001). Sustained clearance of serum HCV-RNA following a course of antiviral treatment is the major determinant of liver fibrosis regression in HIV/HCV-coinfected patients.


Subject(s)
Antiviral Agents/therapeutic use , HIV Infections/complications , Hepatitis C, Chronic/complications , Hepatitis C, Chronic/drug therapy , Interferon-alpha/therapeutic use , Liver Cirrhosis/epidemiology , Ribavirin/therapeutic use , Cohort Studies , Elasticity Imaging Techniques , Female , Humans , Liver Cirrhosis/diagnosis , Male , Retrospective Studies , Treatment Outcome
14.
Genes Immun ; 15(1): 16-24, 2014 Jan.
Article in English | MEDLINE | ID: mdl-24173146

ABSTRACT

Several data suggest that low-density lipoprotein receptor (LDLR) is a co-receptor for hepatitis C virus (HCV). Soluble LDLR can inhibit HCV infectivity; greater plasma low-density lipoprotein levels are associated with treatment success; LDLR genotypes have a synergistic impact on the likelihood of achieving SVR with Peg-IFN plus RBV, as well as on viral kinetics after starting treatment. The objective of this study was to assess the impact of genetic polymorphisms in genes related to cholesterol synthesis and transport pathways on pre-treatment plasma HCV viral load (VL). A total of 442 patients infected with HCV and treatment naive were prospectively recruited. One hundred forty-four SNPs located in 40 genes from the cholesterol synthesis/transport and IL28B were genotyped and analyzed for genetic association with pre-treatment plasma HCV VL. SNPs rs1433099 and rs2569540 of LDLR showed association with plasma HCV VL (P=4 × 10(-4) and P=2 × 10(-3)) in patients infected with genotypes 1 and 4. A haplotype including the last three exons of LDLR showed association with the cutoff level of 600 000 IU ml(-1) VL for genotypes 1 and 4 (OR=0.27; P=8 × 10(-6)), as well as a quantitative VL (mean±s.d.: 6.19±0.9 vs CC+CG 5.58±1.1 logIU ml(-1), P=8 × 10(-5)). LDLR genotypes are a major genetic factor influencing HCV VL in patients infected with genotypes 1 and 4.


Subject(s)
Hepacivirus/genetics , Hepatitis C/genetics , Hepatitis C/virology , Polymorphism, Single Nucleotide , Receptors, LDL/genetics , Viral Load , Adult , Cholesterol/genetics , Cholesterol/metabolism , Coinfection , Exons , Female , HIV Infections/genetics , HIV Infections/virology , Haplotypes , Hepacivirus/pathogenicity , Humans , Interferons , Interleukins/genetics , Male , Middle Aged
15.
Eur J Clin Microbiol Infect Dis ; 32(11): 1427-35, 2013 Nov.
Article in English | MEDLINE | ID: mdl-23715768

ABSTRACT

The aim of this study was to assess the impact of the genetic pattern (GP) defined by the single nucleotide polymorphisms (SNPs) rs14158 of low-density lipoprotein receptor (LDLR) and rs12979860 of interleukin-28B (IL28B) genes on the outcome and features of hepatitis C virus (HCV) infection in patients with and without human immunodeficiency virus (HIV) coinfection. 314 HIV/HCV-coinfected and 109 HCV-monoinfected patients treated with pegylated interferon (Peg-IFN) plus ribavirin (RBV), as well as 51 patients with HCV spontaneous clearance (SC), were included. Variations in both SNPs were determined by the TaqMan polymerase chain reaction (PCR) assay. In the 286 patients chronically infected by HCV genotypes 1 or 4, both rs14158 CC and rs12979860 CC were associated with a higher rate of sustained virological response (SVR), and these effects were complementary in both HCV-monoinfected and HIV/HCV-coinfected patients. Thus, 24 % of patients with rs14158/rs12979860 TT-TC/TT-TC, 33 % with TT-TC/CC, 44.2 % with CC/TT-TC, and 75.8 % harboring CC/CC attained SVR (p < 0.001). SC was associated with the IL28B genotype (66.7 % CC in SC vs. 42.6 % among those with chronic infection, p < 0.001) but not with the LDLR genotype. There was no association between GP and the plasma level of alanine aminotransferase (ALT) or the presence of advanced fibrosis. There is a complementary effect between the IL28B and LDLR genotypes on the probability of achieving SVR after Peg-IFN/RBV therapy in patients with HCV 1 or 4. Thus, the predictive value of IL28B genotype is modulated by the LDLR genotype in both HCV-monoinfected and HIV/HCV-coinfected patients. This complementary effect of both genotypes is also observed on the plasma levels of low-density lipoprotein cholesterol (LDL-C).


Subject(s)
Hepatitis C, Chronic/drug therapy , Hepatitis C, Chronic/genetics , Interleukins/genetics , Polymorphism, Single Nucleotide , Receptors, LDL/genetics , Adult , Antiviral Agents/therapeutic use , Female , HIV Infections/complications , Humans , Interferons/therapeutic use , Male , Middle Aged , Ribavirin/therapeutic use , Treatment Outcome
16.
Actual. anestesiol. reanim ; 21(4): 58-64, oct.-dic. 2011. tab
Article in Spanish | IBECS | ID: ibc-97647

ABSTRACT

La cefalea postpunción dural (CPPD) es el resultado de la punción advertida o inadvertida de la duramadre. Es la complicación más frecuente de la anestesia neuroaxial. Los mecanismos fisiopatológicos siguen siendo discutidos. La mayoría de las veces se resuelve espontáneamente pero en ocasiones persiste meses. Su tratamiento es controvertido porque la evidencia científica es escasa. El siguiente artículo revisa la incidencia, fisiopatología, clínica, diagnóstico, prevención y tratamiento de la CPPD(AU)


Postdural puncture headache (PDPH) is the result of the puncture warned or unnoticed of dura mater. It is the most common complication following neuroaxial anesthesia. Physiopathological mechanisms remain discussed. Most of the times it solves spontaneously but sometimes it persists months. Its treatment is controversial because the scientific evidence is scarce. The following article reviews the incidence, physiopathology, clinical, diagnosis, prevention and treatment of the PPH(AU)


Subject(s)
Humans , Anesthesia, Epidural/adverse effects , Post-Dural Puncture Headache/epidemiology , Blood Patch, Epidural , Risk Factors
17.
HIV Med ; 12(8): 487-93, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21375685

ABSTRACT

OBJECTIVES: The C allele of the single nucleotide polymorphism rs12979860, located near the interleukin-28B (IL-28B) gene, has a strong impact on hepatitis C virus (HCV) treatment response, as well as on spontaneous viral clearance. In patients with chronic hepatitis C (CHC), genotype CC carriers harbour HCV genotype 3 more commonly than those with non-CC genotypes. The aim of this study was to compare the HCV genotype distributions, according to IL-28B genotype, in HIV-infected patients with CHC and those with acute hepatitis C (AHC). METHODS: The rs12979860 genotype was determined by polymerase chain reaction (PCR) in two subpopulations of HIV-infected patients. The first consisted of 80 German patients with AHC. The second consisted of 476 patients with CHC, belonging to one German and two Spanish cohorts. RESULTS: In the AHC group, 31 (81.6%) rs12979860 CC carriers were infected with HCV genotype 1 or 4 vs. 32 (76.2%) among non-CC carriers (P=0.948). In patients with CHC, among those with the CC genotype, 119 (54.6%) were infected with HCV genotype 1 or 4 and 99 (45.4%) with genotype 2 or 3, whereas in the subset with non-CC genotypes, 200 (77.5%) harboured HCV genotype 1 or 4 and 58 (22.5%) genotype 2 or 3 (P<0.001). CONCLUSIONS: Among HIV-infected patients with CHC, those bearing the IL-28B genotype CC were more commonly infected with genotype 3 than subjects with non-CC genotypes, whereas in HIV-infected subjects with AHC this finding was not obtained. These results strongly suggest that the protective effect of the CC genotype against evolution to CHC is mainly exerted in patients infected with HCV genotype 1 or 4.


Subject(s)
Hepacivirus/genetics , Hepatitis C, Chronic/virology , Hepatitis C/virology , Interleukins/genetics , Adult , Coinfection , Female , Genotype , HIV Infections/complications , HIV Infections/virology , Hepacivirus/classification , Hepatitis C/complications , Hepatitis C/genetics , Hepatitis C, Chronic/complications , Hepatitis C, Chronic/genetics , Humans , Interferons , Male , Middle Aged , Polymorphism, Single Nucleotide
18.
J Viral Hepat ; 18(1): 11-6, 2011 Jan.
Article in English | MEDLINE | ID: mdl-20088890

ABSTRACT

Liver damage may result from multiple factors in HIV-infected patients. The availability of reliable noninvasive tools to measure liver fibrosis has permitted the screening of large patient populations. Cross-sectional study of all consecutive HIV outpatients who underwent examination by transient elastometry (FibroScan) at one HIV reference clinic during 2007. Advanced liver fibrosis (ALF) was defined as hepatic stiffness >9.5 kilopascals, which corresponds to Metavir stages F3-F4 in the liver biopsy. A total of 681 consecutive HIV-infected patients (64% injecting drug users; mean age 43; 78% male; 98% on antiretroviral therapy) had at least one valid FibroScan evaluation. ALF was diagnosed in 215 (32%) of them. In the univariate analysis, ALF was significantly associated with older age, low CD4 counts, chronic hepatitis C, past alcohol abuse, elevated ALT, high triglycerides, low cholesterol, high homeostasis model assessment (HOMA) index and exposure to didanosine and/or stavudine. In a multivariate model (OR, 95% CI), chronic hepatitis C (2.83, 1.57-5.08), past alcohol abuse (2.26, 1.37-3.74), exposure to didanosine and/or stavudine (1.85, 1.14-3.01), high HOMA index (1.25, 1.04-1.51), older age (1.09, 1.05-1.14) and elevated ALT (1.04, 1.03-1.06) remained as independently associated with ALF. Therefore, in addition to chronic hepatitis C and alcohol abuse, insulin resistance and/or exposure to dideoxy-nucleosides may contribute to ALF in HIV-infected patients.


Subject(s)
Anti-HIV Agents/adverse effects , HIV Infections/complications , Hepatitis C, Chronic/complications , Insulin Resistance , Liver Cirrhosis/etiology , Reverse Transcriptase Inhibitors/adverse effects , Adult , Anti-HIV Agents/therapeutic use , Antiviral Agents/therapeutic use , Cross-Sectional Studies , Didanosine/adverse effects , Didanosine/therapeutic use , Female , HIV Infections/drug therapy , Hepacivirus/drug effects , Hepatitis C, Chronic/drug therapy , Humans , Liver Cirrhosis/pathology , Male , Reverse Transcriptase Inhibitors/therapeutic use , Risk Factors , Stavudine/adverse effects , Stavudine/therapeutic use
19.
J Viral Hepat ; 18(5): 325-30, 2011 May.
Article in English | MEDLINE | ID: mdl-20456635

ABSTRACT

The efficacy of current hepatitis C therapy in HIV/HCV-coinfected patients is largely dependent on HCV genotype. The annual prevalence of HCV genotypes/subtypes and their influence on HCV clearance with antiviral treatment were examined in a dynamic cohort of HIV/HCV-coinfected patients followed up in Madrid since 2000. Patients entered the cohort at first visit and left the cohort when HCV clearance was achieved with HCV therapy or when follow-up was interrupted for any reason, including death. A total of 672 HIV/HCV-coinfected patients constituted the cohort. The mean follow-up time was 5.5 years, corresponding to 4108 patient-years. Mean age at entry was 37 years, and 73% were men and 86% were intravenous drug users. Overall distribution of HCV genotypes was as follows: 57.1% HCV-1 (1a: 29.2%, 1b: 20.4%, unknown: 7.6%), 1.3% HCV-2, 25.4% HCV-3 and 15.9% HCV-4. A total of 274 (40.8%) patients were treated with peginterferon-ribavirin, of whom 116 (42.3%) achieved HCV clearance following 1-3 courses of therapy. The proportion of HCV-1/4 rose from 71.7% in 2000 to 76.8% in 2008, whereas the proportion of HCV-2/3 fell from 28.1% in 2000 to 23.2% in 2008. The yearly prevalence increased for HCV-1 (R(2) : 0.92, b: 0.59, P < 0.001) and HCV-4 (R(2) : 0.77, b: 0.33, P < 0.005) and conversely diminished for HCV-3 (R(2) : 0.94, b: -0.82, P < 0.001). In summary, the prevalence of HCV-1 and HCV-4 has increased over the last decade in HIV/HCV-coinfected patients, whereas conversely it has declined for HCV-3, in association with the wider use of HCV therapy (41%) in this population.


Subject(s)
Antiviral Agents/therapeutic use , HIV Infections/epidemiology , Hepacivirus/genetics , Hepatitis C/drug therapy , Hepatitis C/epidemiology , Adult , Antiviral Agents/administration & dosage , Cohort Studies , Drug Therapy, Combination/trends , Follow-Up Studies , Genotype , HIV Infections/complications , HIV Seropositivity , Hepacivirus/classification , Hepacivirus/drug effects , Hepatitis C/complications , Hepatitis C/virology , Humans , Incidence , Interferons/therapeutic use , Male , Population Dynamics , Prevalence , RNA, Viral/blood , RNA, Viral/genetics , Ribavirin/therapeutic use , Substance Abuse, Intravenous
20.
J Viral Hepat ; 18(8): 542-8, 2011 Aug.
Article in English | MEDLINE | ID: mdl-20819149

ABSTRACT

The greatest benefit of hepatitis C virus (HCV) therapy is seen in cirrhotics attaining sustained virological response (SVR). However, concerns about toxicity and poorer responses often discourage treatment of cirrhotics. This may be particularly relevant in HIV-HCV-coinfected patients, in whom progression of liver fibrosis is faster and treatment responses lower. This is a retrospective analysis of HIV-HCV-coinfected patients who had received peginterferon-ribavirin therapy at our institution. Individuals naïve for interferon in whom liver fibrosis had been assessed using elastometry within the year before being treated were chosen. Response rates and toxicities were compared in cirrhotics (>14.5 KPa) and noncirrhotics. Patients with previous liver decompensation were excluded. Overall, 41 cirrhotics and 190 noncirrhotics entered the study. Groups were similar in age, gender, HCV genotypes and baseline serum HCV-RNA. SVR occurred at similar rates in cirrhotic and noncirrhotics, either considered by intention-to-treat (39%vs 45%; P = 0.4) or as treated (50%vs 52%, P = 0.8). In multivariate analysis (odds ratio, 95% CI, P), SVR was associated with HCV genotypes 2-3 (5, 2.9-11, <0.01) and lower serum HCV-RNA (2, 1.4-3.03 for every log decrease, <0.01) but not with cirrhosis (1.2, 0.4-3.6, 0.6). Treatment discontinuations because of adverse events tended to be more common in cirrhotics than in noncirrhotics (17%vs 12%; P = 0.2), but only severe thrombocytopenia was more frequent in cirrhotics than in non-cirrhotics (20%vs 3% at week 24; P < 0.01). Response to peginterferon-ribavirin therapy is similar in HIV-HCV coinfected patients with and without liver cirrhosis. Therefore, treatment must be encouraged in all compensated cirrhotic patients, although closer monitoring and management of side effects, mainly thrombocytopenia, may be warranted.


Subject(s)
HIV Infections/complications , Hepacivirus/drug effects , Hepatitis C, Chronic/drug therapy , Liver Cirrhosis/drug therapy , Liver/pathology , Adult , Drug Combinations , Female , HIV/drug effects , HIV/pathogenicity , HIV Infections/drug therapy , HIV Infections/virology , Hepacivirus/pathogenicity , Hepatitis C, Chronic/complications , Hepatitis C, Chronic/virology , Humans , Interferon alpha-2 , Interferon-alpha/administration & dosage , Interferon-alpha/adverse effects , Interferon-alpha/therapeutic use , Liver/virology , Liver Cirrhosis/complications , Liver Cirrhosis/virology , Male , Middle Aged , Polyethylene Glycols/administration & dosage , Polyethylene Glycols/adverse effects , Polyethylene Glycols/therapeutic use , RNA, Viral/blood , Recombinant Proteins , Retrospective Studies , Ribavirin/administration & dosage , Ribavirin/adverse effects , Ribavirin/therapeutic use , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...